Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
SGBI's Cash to Debt is ranked lower than
65% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. SGBI: No Debt )
SGBI' s 10-Year Cash to Debt Range
Min: 0.13   Max: No Debt
Current: No Debt

Equity to Asset 2.07
SGBI's Equity to Asset is ranked lower than
87% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SGBI: 2.07 )
SGBI' s 10-Year Equity to Asset Range
Min: -6.52   Max: 2.07
Current: 2.07

-6.52
2.07
F-Score: 5
Z-Score: -268.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -737.02
SGBI's Operating margin (%) is ranked lower than
79% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. SGBI: -737.02 )
SGBI' s 10-Year Operating margin (%) Range
Min: -29083.33   Max: 100
Current: -737.02

-29083.33
100
Net-margin (%) -801.66
SGBI's Net-margin (%) is ranked lower than
79% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. SGBI: -801.66 )
SGBI' s 10-Year Net-margin (%) Range
Min: -25450   Max: -194.09
Current: -801.66

-25450
-194.09
ROE (%) -236.32
SGBI's ROE (%) is ranked lower than
71% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. SGBI: -236.32 )
SGBI' s 10-Year ROE (%) Range
Min: -552.97   Max: -45.47
Current: -236.32

-552.97
-45.47
ROA (%) -350.99
SGBI's ROA (%) is ranked lower than
65% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. SGBI: -350.99 )
SGBI' s 10-Year ROA (%) Range
Min: -1075.35   Max: -43.77
Current: -350.99

-1075.35
-43.77
ROC (Joel Greenblatt) (%) -1006.79
SGBI's ROC (Joel Greenblatt) (%) is ranked lower than
66% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. SGBI: -1006.79 )
SGBI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -116333.33   Max: 9.24
Current: -1006.79

-116333.33
9.24
EBITDA Growth (%) -20.60
SGBI's EBITDA Growth (%) is ranked lower than
114% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. SGBI: -20.60 )
SGBI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 44.2
Current: -20.6

0
44.2
EPS Growth (%) -20.60
SGBI's EPS Growth (%) is ranked lower than
111% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. SGBI: -20.60 )
SGBI' s 10-Year EPS Growth (%) Range
Min: -45   Max: 26
Current: -20.6

-45
26
» SGBI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with SGBI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 39.30
SGBI's P/S is ranked lower than
61% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. SGBI: 39.30 )
SGBI' s 10-Year P/S Range
Min: 2.5   Max: 74
Current: 39.3

2.5
74
EV-to-EBIT -5.11
SGBI's EV-to-EBIT is ranked lower than
61% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SGBI: -5.11 )
SGBI' s 10-Year EV-to-EBIT Range
Min: -51   Max: -1.9
Current: -5.11

-51
-1.9
Current Ratio 0.76
SGBI's Current Ratio is ranked lower than
66% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. SGBI: 0.76 )
SGBI' s 10-Year Current Ratio Range
Min: 0.08   Max: 60.47
Current: 0.76

0.08
60.47
Quick Ratio 0.76
SGBI's Quick Ratio is ranked lower than
66% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. SGBI: 0.76 )
SGBI' s 10-Year Quick Ratio Range
Min: 0.03   Max: 59.85
Current: 0.76

0.03
59.85

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -19.60
SGBI's Earnings Yield (Greenblatt) is ranked lower than
69% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. SGBI: -19.60 )
SGBI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -19.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:LH, ALR, DGX, LIFE, ENZ » details
Sangui BioTech International Inc began operations in October 1996. In August 1997, a publicly held company, Citadel Investment System, Inc., a Colorado corporation (Citadel), acquired one hundred percent of the outstanding common shares of Sangui BioTech, Inc., and as a result, Sangui BioTech, Inc. became a wholly owned subsidiary of Citadel. Thereafter, Citadel changed its name to Sangui BioTech International, Inc. (the Company or SGBI). The Company's mission is the development of novel and proprietary pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, Sangui GmbH. The Company's focus has been the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. SanguiBio GmbH holds the exclusive distribution rights for Chitoskin wound pads for the European Union and various other countries. The Company develops several products based on polymers of purified natural porcine hemoglobin with oxygen carrying abilities that are similar to those of native hemoglobin. These are oxygen carrying blood additives, and oxygen carrying blood volume substitutes. It is subject to governmental regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, and other similar laws of general application.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK